Scilex Enters Exclusive License Agreement with Datavault AI
Scilex Holding Company (SCLX) has entered an exclusive License Agreement with Datavault AI Inc. on November 3, 2025, allowing Scilex to use Datavault’s AI technology in biotech and biopharma. The agreement includes a $10 million non-refundable fee and potential milestone payments of up to $2.55 billion. This strategic move aims to create a Biotech Exchange platform and tokenize pharmaceutical sales. Analysts rate SCLX stock as a Buy with a $770.00 price target. Scilex focuses on non-opioid pain management products and has a market cap of $135.5M.
The latest announcement is out from Scilex Holding Company ( (SCLX) ).
On November 3, 2025, Scilex Holding Company entered into a License Agreement with Datavault AI Inc., granting Scilex a worldwide, exclusive license to Datavault’s AI-driven technology for use in the biotech and biopharma industries. This agreement enables Scilex to utilize Datavault’s advanced data platforms for secure tokenization and monetization of biotech assets, marking a significant advancement in the commercialization of biotech innovations. The license agreement includes a non-refundable fee of $10 million, payable in installments, and potential milestone payments up to $2.55 billion. This strategic move positions Scilex to potentially revolutionize the pharmaceutical industry by creating a Biotech Exchange platform and exploring opportunities to tokenize pharmaceutical drug and diagnostic sales.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases. The company targets indications with high unmet needs and large market opportunities, offering non-opioid therapies to improve patient outcomes. Scilex’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, and it is developing additional product candidates such as SP-102, SP-103, and SP-104.
Average Trading Volume: 244,894
Technical Sentiment Signal: Sell
Current Market Cap: $135.5M
